Robert M Straubinger
Overview
Explore the profile of Robert M Straubinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moloney C, Roy Chaudhuri T, Straubinger R, Brougham D
J Mater Chem B
. 2025 Jan;
13(6):2203-2209.
PMID: 39807068
Magnetic chromatography was exploited to fractionate suspensions of magnetoliposomes (SML: lumen-free lipid-encapsulated clusters of multiple magnetic iron-oxide nanoparticles) improving their colloidal properties and relaxivity (magnetic resonance image contrast capability). Fractionation...
2.
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
Jarvi N, Patel M, Shetty K, Nguyen N, Grasperge B, Mager D, et al.
Front Immunol
. 2024 Dec;
15():1496169.
PMID: 39720710
Introduction: Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a...
3.
Miao X, Shen S, Koch G, Wang X, Li J, Shen X, et al.
J Pharm Sci
. 2024 Mar;
113(1):214-227.
PMID: 38498417
Pancreatic ductal adenocarcinoma (PDAC) is often chemotherapy-resistant, and novel drug combinations would fill an unmet clinical need. Previously we reported synergistic cytotoxic effects of gemcitabine and trabectedin on pancreatic cancer...
4.
Alruwaili M, Zonneville J, Naranjo M, Serio H, Melendy T, Straubinger R, et al.
Cell Rep Med
. 2024 Feb;
5(3):101434.
PMID: 38387463
The tumor-suppressor p53 is commonly inactivated in colorectal cancer and pancreatic ductal adenocarcinoma, but existing treatment options for p53-mutant (p53) cancer are largely ineffective. Here, we report a therapeutic strategy...
5.
Lin Q, Serratore A, Niu J, Shen S, Roy Chaudhuri T, Ma W, et al.
Drug Resist Updat
. 2024 Feb;
73:101064.
PMID: 38387284
Aims: Pancreatic ductal adenocarcinoma (PDAC) is often intrinsically-resistant to standard-of-care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can arise from treatment of initially-sensitive tumors, and chemotherapy can increase tumor...
6.
Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Roy Chaudhuri T, Lin Q, Stachowiak E, Rosario S, Spernyak J, Ma W, et al.
Clin Cancer Res
. 2024 Jan;
30(7):1367-1381.
PMID: 38270582
Purpose: Paracrine activation of pro-fibrotic hedgehog (HH) signaling in pancreatic ductal adenocarcinoma (PDAC) results in stromal amplification that compromises tumor drug delivery, efficacy, and patient survival. Interdiction of HH-mediated tumor-stroma...
7.
Lin Q, Serratore A, Perri J, Roy Chaudhuri T, Qu J, Ma W, et al.
Br J Pharmacol
. 2023 Nov;
181(9):1383-1403.
PMID: 37994108
Background And Purpose: Elevated fibroblast growth factor receptor (FGFR) activity correlates with pancreatic adenocarcinoma (PDAC) progression and poor prognosis. However, its potential as a therapeutic target remains largely unexplored. Experimental...
8.
Miao X, Koch G, Shen S, Wang X, Li J, Shen X, et al.
J Pharm Sci
. 2023 Nov;
113(1):235-245.
PMID: 37918792
Despite decades of research efforts, pancreatic adenocarcinoma (PDAC) continues to present a formidable clinical challenge, demanding innovative therapeutic approaches. In a prior study, we reported the synergistic cytotoxic effects of...
9.
Rasam S, Lin Q, Shen S, Straubinger R, Qu J
J Proteome Res
. 2023 Oct;
22(12):3780-3792.
PMID: 37906173
Pancreatic cancer patients have poor survival rates and are frequently treated using gemcitabine (Gem). However, initial tumor sensitivity often gives way to rapid development of resistance. Gem-based drug combinations are...
10.
Wang J, Chen T, Ruszaj D, Mager D, Straubinger R
J Pharm Sci
. 2023 Oct;
113(1):72-84.
PMID: 37844759
Therapeutic antibodies have shown little efficacy in the treatment of pancreatic ductal adenocarcinomas (PDAC). Tumor desmoplasia, hypovascularity, and poor perfusion result in insufficient tumor cell exposure, contributing to treatment failure....